The United Kingdom, the first country to approve a bivalent vaccine against covid-19

The United Kingdom on Monday became the first country to approve Moderna’s bivalent vaccine developed to attack the original covid-19 virus and the new one. omicron variant, The Medicines and Healthcare Products Regulatory Agency (MHRA) reported.

With this decision, it is expected that the vaccine will be used as a booster in the coming autumn, although at the moment the amount of vaccine is unknown. doses that are available.

The health authorities had already indicated that starting next September a booster shot to the over 50 years old and to people who are in the highest risk groups.

The original vaccines used during the pandemic were developed to combat the original form of the virus that emerged in Wuhan, China, in late 2019, but the virus has since mutated as new variants emerged that can evade the virus. immune system, which has caused outbreaks of evil in many countries. With this bivalent vaccine, it is expected that only a single injection will be needed in adults once a year.

Known as mRNA-1273.214, the dose is an updated version of the Moderna vaccine that is already given as a first, second and booster dose, and is now an approved dose in the UK that targets two strains of the virus. According to the MHRA, side effects from the vaccine are the same as those seen with Moderna’s original booster dose and were generally mild.

MHRA Executive Director June Raine described the new booster as "a sharp tool in our arsenal" to protect the UK against covid-19.

Read Also:  Where To Get Free Copies Of Your Credit Reports

"I am pleased to announce the approval of the Moderna bivalent booster vaccine" for the purpose of "provide a strong immune response against the Omicron BA.1 variant as well as the original 2020 strain"Raine added.

Moderna’s chief medical officer, Paul Burton, said the new injection can boost a person’s antibodies to levels so high that it may only be needed annually.

Stephane Bancel, CEO of Moderna, described it as a "next generation covid-19 vaccine" who will play a "important role in protecting people in the UK against covid-19" in the winter.

"We are delighted with the MHRA authorization of Spikevax Bivalent Original/Omicron, our next generation Covid-19 vaccine"Bancel stressed to the media.

"This represents the first authorization of a bivalent vaccine containing Omicron, further highlighting the dedication and leadership of the authorities UK public health to help end the covid-19 pandemic"he added.

Recent Articles

Related News

Leave A Reply

Please enter your comment!
Please enter your name here